Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$413 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1
Industry P/E
--
EV/EBITDA
-3.8
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
49,894,131
CFO
CA$-111.75 Mln
EBITDA
CA$-148.61 Mln
Net Profit
CA$-145.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cybin (CYBN)
| -35.9 | -10.5 | -12.4 | -32.8 | -33.1 | -34.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Cybin (CYBN)
| -7.3 | 38.0 | -75.3 | -19.5 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cybin (CYBN)
|
5.2 | 413.1 | 0.0 | -131.6 | -- | -61.8 | -- | 1.0 |
| 71.7 | 669.9 | 0.0 | -19.8 | -- | -28.1 | -- | 10.8 | |
| 0.9 | 86.6 | 0.0 | -35.3 | -- | -1067.3 | -- | 1,236.3 |
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat... major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Address: 100 King Street West, Toronto, ON, Canada, M5X 1C9 Read more
Co-Founder, President & Executive Chairman
Mr. Eric So L.L.B.
Co-Founder, President & Executive Chairman
Mr. Eric So L.L.B.
Headquarters
Toronto, ON
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Cybin Inc (CYBN) is $5.64 (NYSE) as of 06-Mar-2026 09:30 EDT. Cybin Inc (CYBN) has given a return of -33.05% in the last 3 years.
Since, TTM earnings of Cybin Inc (CYBN) is negative, P/E ratio is not available.
The P/B ratio of Cybin Inc (CYBN) is 1.03 times as on 06-Mar-2026, a 66 discount to its peers’ median range of 3.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.21
|
0.58
|
|
2024
|
-0.67
|
0.18
|
|
2023
|
-1.89
|
0.99
|
|
2022
|
-1.99
|
1.65
|
|
2021
|
-5.11
|
113.61
|
The 52-week high and low of Cybin Inc (CYBN) are Rs 9.83 and Rs 4.81 as of 02-Apr-2026.
Cybin Inc (CYBN) has a market capitalisation of $ 413 Mln as on 06-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cybin Inc (CYBN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-2.25
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.